2023

• Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes
  Yang et al., Vaccines (2023) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilities
• Breznik et al., The Lancet (2023) 
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
  Thibaudin et al., Nature Medicine (2023) - PMID: 37563240
  Products used: PepMix Human (NY-ESO-1)
• Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reaction
  Hayashi et al., Scientific Reports (2023) - PMID: 37563266
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice
  Dasari et al., Nature Communications (2023) - PMID: 37553346
  Products used: PepMix EBV (GP350/GP340)
• Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
  Pasquevich et al., Nature Communications (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
• Zika virus infection during pregnancy and vertical transmission: case reports and peptide-specic cellmediated immune responses
  Soudeyns et al., Research Sqaure (2023) 
  Products used: PepMix HCMVA (pp65), ZIKV (NS1) Ultra, ZIKV (C) Ultra, ZIKV (E) Ultra
• YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge
  Lemmens et al., Vaccines (2023) 
  Product used: PepMix Zaire Ebola (GP/Kikwit-95)
• Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19
  Dang et al., Microbiology Spectrum (2023) - PMID: 37428088
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (ORF10), SARS-CoV-2 (ORF9B)
  Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8
• A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation
  Kimura et al., Molecular Therapy (2023) - PMID: 37403357
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)
• Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses
  Hellgren et al., Nature Communications (2023) - PMID: 37349310
  Product used: PepMix Rabies virus (Glycoprotein)
• Immunological imprinting of humoral immunity to SARS-CoV-2 in children
  Dowell et al., Nature Communications - PMID: 37386081
  Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2))
• Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
  Han et al., Nature Nanotechnology (2023) - PMID: 37365276
  Products used: PepMix™ SARS-CoV-2 (S-RBD)
• Characterization of T cell responses to SARS-CoV-2 following infection and vaccination
  Law, Dissertation (2023)
  Products used: PepMix™SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodies
  Montes-Cobos et al., iScience (2023) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response
  Ladhani et al., The Lancet (2023) - PMID: 37336224
  Product used: Custom PepMix
• Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory Diseases
  Cheung et al., Journal of Immunology (2023) - PMID: 37326480
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised Individual
  Bunse et al., Microorganisms (2023) - PMID: 37375064
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles
  Sweeney et al., Cytotherapy (2023) - PMID: 37278683
  Products used: custom PepMix
• High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primates
  Le Grand et al., Research Square (2023) 
  Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP)
• A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge
  Reguzova et al., Research Square et al., (2023) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus
  Brzuska et al., Microbiology Spectrum (2023) - PMID: 37199661
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors
  Echarri et al., Frontiers Sports Act. Living (2023) - PMID: 37252426
  Product used: PepMix™ HCMVA (pp65) & VZV (IE63)
• Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy
  Macková et al., Leukemia Research (2023) - PMID: 37216792
  Product used: PepMix™ SARS-CoV-2 (NCAP)
• Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in Peoplen with HIV
  Verburgh et al., Microbiology Spectrum (2023) - PMID: 37166335
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG
  Dijkman et al., Vaccines (2023) - PMID: 37160970
  Product used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (PPE68), M. tuberculosis (EspA), PepMix M. tuberculosis (MPT64) & custom PepMix (for EspI, EspC, MPT70, MPT83), 
• Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens
  Nantambi et al., Frontiers in Immunology (2023) - PMID: 37153598
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoproteins)
• High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
  Nuñez et al., Nature Immunology (2023) - PMID: 37095378
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
  Dietz et al., Communications Medicine (2023) - PMID: 37095240
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
  Hoffmann et al., Cell (2023) - PMID: 37146611
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient
  Morita et al., iScience (2023) - PMID: 37124420
  Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins
• Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
  Sharma et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37072346
  Product used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2) & EBV (BARF1)
• Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
  Baker et al., Brain, Behaviour & Immunity (2023) - PMID:  36743994
  Products used: PepMix™ Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)
• A cell-free antigen processing system informs HIV-1 epitope selection and vaccine design
  Sengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141
  Product used: PepMix™ HIV-1 (NEF) Ultra & HIV-1 (Con B gag motif)
• Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
  Koldehoff  et al., Vaccines (2023) - PMID: 37112757
  Product used: PepMix™ BKV (capsid protein VP1) & BKV (large T antigen)
• Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B
  Fu et al., Hepatology International (2023) - PMID: 36976426
  Product used: PepMix™ HBV (Capsid Protein) Ultra & HBV (LEP) Ultra
• Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort Study
  Ferreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)
• Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2
  Phan et al., Journal of Immunology (2023) - PMID: 36961450
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
  Saeland et al., Vaccines (2023) - PMID: 36949051
  Product used: PepMix HRSVA (Fusion Glycoprotein F0)
• Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered
  López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
  
• SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies
  Shrivastava et al., Vaccines (2023) - PMID: 36934088
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms
  D'Alessio et al., Vaccines (2023) - PMID: 36992261
  Product used: PepMix™ SARS-CoV-2 (S-RBD)
• Spezifische T-Zellantwort und Immunevasion beim humanen Herpesvirus 6 und SARS-CoV-2
  Hollaus, Dissertation (2023)
• Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase
  Myeni et al., Nature Communications (2023) 
  Product used: PepMix MERS-CoV (Spike Glycoprotein)
• Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.
  Muir et al., MedRxiv (2023) 
  Product used: PepMix HBV (Large envelope protein)
• A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines
  Ryan et al., Cell Reports Medicine (2023) 
  Product used: PepMix Chimpanzee Adenovirus Y25 (Hexon Protein)
• Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral Variants
  Montgomerie et al., IScience (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell development
  Scherer et al., Nature Immunology (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
  Nanishi et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models
  Corleis et al., Nature Communications (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• The role of the T-cell mediated immune response to Cytomegalovirus infection in intrauterine transmission
  Soriano-Ramos et al., PLOS One (2023) 
  Products used: PepMix HCMVA (IE-1) & HCMVA (pp65)
• Multimodal single‑cell analyses of peripheral blood mononuclear cells of COVID‑19 patients in Japan
  Kashima et al., Scientific Reports (2023) - PMID: 36732528
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), ....ORF3a/6/7a/7b/8/9b/10
• Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic Influenza
  Tjärnhage et al., Journal of Virology (2023) 
  Products used: PepMix Influenza A (HA/Puerto Rico/8/1934 H1N1) & Influenza A (HA /California (H1N1))
• Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
  Gressens et al., Vaccines (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2
  Yin et al., BioRxiv (2023) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2
  Baker et al., Brain Behaviour & Immunity - Health (2023) 
  Products used: PepMix Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)
• The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
  Liu et al., Communications Biology (2023)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
  Emmelot et al., Viruses (2023)
• Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial
  Øverbø et al., Vaccine (2023) 
  Product used: PepMix HEV (ORF2)
• A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic cats
  Conforti et al., Molecular Therapy (2023) 
  Product used: PepMix SARS-CoV-2 (S-RBD)
• Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study
  Thuluva et al., MedRxiv (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD)
• The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses
  Soni et al., BioRxiv (2023)
• Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models
  Roth et al., BioRxiv (2023)
  Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
  Klebanoff et al., MedRxiv (2023) 
  Products used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (Spike Glycoprotein)
• An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animals
  Offersgaard et al., iScience (2023)
  Products used: SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
  Pasquevich et al., MedRxiv (2023)
  Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)
• Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge
  Lemmens et al., BioRxiv (2023)
  Products used: PepMix Zaire Ebola (GP/Kikwit-95), Yellow fever (NS4B)

2022

• Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: An explanatory study in Japan
  Yamaguchi et al., The Lancet (2023) 
  Product used: PepMix SARS-CoV-2 (Spike), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
  Keppler-Hafkemeyer et al., Nature Cancer (2023) - PMID: 36543907
  Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), Human Adenovirus 5 (Hexon Protein), HCoV-OC43 (Spike Glycoprotein), SARS-CoV-2 (NCAP)
• Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challenge
  Jia et al., Communications Biology (2022) 
  Products used: PepMix M. tuberculosis (Ag85B), M. tuberculosis (EspA), M. tuberculosis (EsxN), M. tuberculosis (TB8.4), M. tuberculosis (MPT64), custom PepMix (EsxH, EsxB, EsxA, ppe68)
• A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines
  Gomez et al., Vaccines (2022) - PMID: 36543794
  Products used: PepMix Zaire Ebola (GP/Mayinga-76)
• Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
  Sabatino et al., Multiple Sclerosis and Related Disorders (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Comprehensive Analysis of Epstein-BarrVirus LMP2A-Specific CD8+ and CD4+ T Cell Responses Restricted to Each HLA Class I and II Allotype Within an Individual
  Jo et al., Immune Network (2022) 
  Product used: PepMix EBV (LMP2)
• Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
  Mrak et al., Journal of Autoimmunity (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice
  Toomer et al., Viruses (2022) - PMID: 36423193
• Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection
  Jacobsen et al., Nature Communications (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients
  Vasileiou et al., Haemtologica (2022) 
  Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8)
• SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients
  Panizo et al., Microorganisms (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosis
  Kim et al., Research Square (2022)
  Products used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (CFP-10), M. tuberculosis (Ag85B)
• Four-Parameter FluoroSpot Assay Reveals That the Varicella Zoster Virus Elicits a Robust Memory T Cell IL-10 Response throughout Childhood
  Nilsson et al., Journal of Virology (2022) - PMID: 36314824
  Products used: PepMix VZV (IE63) & VZV (gE)
• Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
  Friberg et al., Vaccines (2022) - PMID: 36316335
  Product used: PepMix Dengue 1 (E) Ultra
• Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
  Kirchner et al., PLoS One (2022) - PMID: 36322587
  Products used: PepMix Pan-SARS-CoV-2 Select, SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), HCoV-229E (Spike Glycoprotein), HCoV-OC43 (Spike Glycoprotein), HRSVB (Nucleocapsid Protein N), Influenza A (M1) Ultra
• Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19
  Epis et al., Pharmacological Research (2022) - PMID: 36336215
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
  Agrati et al., The Lancet (2022)
  Products used: PepMix Vaccinia virus (MVA105L), Vaccinia virus (MVA074R), Vaccinia virus (MVA121L)
• SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
  Imhof et al., Infectious Disease (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variants
  Hu et al., Molecular Therapy (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant Recipients
  Del Bello et al., Vaccines (2022) - PMID: 36146517
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
  Lenart et al., Molecular Therapy (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines
  Greer, Dissertation (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha)
• Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern
  Akache et al., Vaccines (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
  Lam et al., ACS Nano (2022) -
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults
  Palacios-Pedrero et al., Nature Aging (2022) 
  Product used: PepMix SARS-CoV-2 (NCAP)
• Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika
  Brzuska, Dissertation (2022)
  Products used: PepMix ZIKV (E) Ultra and ZIKV (M) Ultra
• Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
  Gunst et al., Nature Medicine (2022) - PMID: 36253609
  Product used: PepMix HIV Gag Ultra
• NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens
  Hielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients
  Busà et al., Vaccines (2022) - PMID: 36298854
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool
• Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19
  Binayke et al., Vaccines (2022) - PMID: 36298628
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose
  Belik et al., Research Square (2022) 
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)
• Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
  Rosás-Umbert et al., Nature Communications (2022)
  Products used: PepMix HIV-1 (GAG) Ultra, HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HIV-1 (POL) Ultra
• Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
  Swaminathan et al., Nature Communications 
  Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Y14)
• Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection
  Khatamzas et al., Nature Communication (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination
  Huang et al., iScience (2022) - PMID: 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer
  Odendahl et al., Immunology Letters (2022) 
  Product used: PepMix HCMVA (pp65)
• Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population
  Sarker et al., Vaccines (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19
  Villemonteix et al., Immunity, Inflammation and Disease (2022) - PMID
  PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP)
  
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
  Hajnik et al., Science Translational medicine (2022) - PMID: 36103514
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  
• A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection
  Ao et al., Journal of Virology (2022) - PMID: 36069551
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)
• SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primates
  Alimohammadi et al., Vaccines (2022) - PMID: 36056015
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patients
  Olea et al., Scientific Reports (2022) - PMID: 35995830
• Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
  Stort et al., Oncoimmunology (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment
  Su et al., ESMO Open (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation
  Azamor et al., Viruses (2022) - PMID: 36146723
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
  Lu et al., Clinical Immunology (2022) 
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
  
• Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an openlabel extension study
  Mrak et al., Annals of Rheumatic Disease (2022) - PMID: 35977809
• Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
  Stone et al., Human Gene Therapy (2022)
• SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
  Terahara et al., iScience (2022) - PMID: 35992306
• Japanese encephalitis virus infection in its natural amplification and reservoir host, the pig
  Redant, Dissertation (2022) 
• Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responses
  Padula et al., Vaccine: X (2022) - PMID: 35936992
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2)
• Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
  Miele et al., Microorganisms (2022)
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP
  
• mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant
  Nanishi et al., Communications Biology (2022) 
• Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
  Renia et al., Nature Communications
• The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockade
  Geisen et al.,  Journal of Medical Virology (2022) - PMID: 35945627
• Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody Deficiency
  Milota et al., Authorea (2022) 
  
• DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret Model
  Compagnone et al., Vaccines (2022) - PMID: 35893826
• SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 Survivors
  Duan et al., Cell Reports (2022) 
  
• Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA1273-boosting with homologous COVID-19 vaccine regimens
  Klemis et al., Nature Communications (2022) 
• Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination
  Sistere-Oro et al., Frontiers in Immunology (2022) 
  
• Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
  Hartl et al., Liver International (2022) - PMID: 35840342
• Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination
  Tang et al., Science Immunology (202) - PMID: 35857583
• Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
  Minnar et al., Journal of Immunology (2022) - PMID: 35764364
  Product used: PepMix HPV 16 (E7)
• Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shot
  Papadopoulou et al., Heliyon (2022) - PMID: 35815135
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
  Quinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956
  Product used: PepMix SARS-CoV-2 (Spike-RBD)
• Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trial
  Robbins et al., The Lancet (2022)
  Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)
• A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing Mice
  Dasari et al., Research Square (2022)
  Product used: PepMix EBV (GP350/GP340)
• Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole Blood
  Oliver et al., Immunohorizons (2022) - PMID: 35750357
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron
  Sieber et al., Frontiers in Immunology (2022) - PMID: 35663948
  Product used: PepMix SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP),  SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)
• Natural Immunity against HIV-1: Progression of Understanding after Association Studies
  Ma Luo, Viruses (2022) 
  Product used: PepMix HIV-1 (GAG) Ultra
• In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
  Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
  Product used: PepMix BKV (Capsid Protein VP1)
• In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation
  
• Najafabadi et al., BMC Immunology (2022) - PMID: 35689183
  Product used: 
• T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cells
  Chu et al., Clinical Chimica Acta (2022) - PMID: 35690083
  Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
• Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans
  Tang et al., Nature Medicine (2022) - PMID: 35668177
  Product used: PepMix S. pyogenes (CAS9)_2 subpools
• A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection
  Tzeng et al., Vaccines (2022)
• Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 Mice
  Kaewborisuth et al., Vaccines (2022)
• Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
  Koldehoff et al., Vaccines (2022)
• SARS-CoV-2 OmicronBA.1 variantbreakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection
  Torres et al., Journal of Medical Virology (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaques
  Zabaleta et al., Molecular Therapy (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
  de Boer et al., Translantation (2022) - PMID: 35546527
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
  Richardson et al., PLoS One (2022) - PMID: 35468147
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)
• Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters
  Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311
  Product used: PepMix™ SARS-CoV (Spike Glycoprotein)
• Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy products
  Durkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022) 
• Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
  Cabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
  Kaaijk et al., Frontiers in Immunology (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein)
• Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderlyresidents of care homes
  Tut et al., Research Square (2022) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
  Woldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)
• USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell Response
  Plummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon)
• mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variant
  Dowling et al., Research Square (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)

• Evaluation of overcoming Limited migration and Enhancing Cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newlydiagnosed glioblastoma
  Randazzo et al., Clinical Trials (2022)
  Product used: PepMix™ HCMVA (pp65) 
• Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximab
  van der Moerden et al., Viruses (2022) 
• Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccination
  Panizo et al., Clinical Kidney Journal (2022) 
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
  Pannus et al., MedRxiv (2022)
• Safety and tolerability of AAV8 delivery of abroadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
  Casazza et al., Nature Medicine (2022) - PMID: 35411076
  Product used: PepMix™ AAV8 (capsid protein)
• NK cells limit therapeutic vaccine–induced CD8+ T cell immunity in a PD-L1–dependent manner
  Diniz et al., Vaccines (2022) - PMID : 35417187
• Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19
  Kaneko et al., Clinical Immunology (2022) - PMID: 35364330
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19
  Venet et al., EBioMedicine (2022) - PMID: 35349827
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
• CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-Dependent
  Popescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444
  Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
  Kroemer et al., Front Public Health (2022) - PMID: 35372242
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)
• High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infection
  Jacobsen et al., Research Square (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
  Lim et al., Nature Cancer (2022) - PMID : 35332334
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
  Palladino et al., Methods and Clinical Development (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP) 
• Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
  Gallais et al., Frontiers in Immunology (2022) - PMID: 35281046
  Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
  Duengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
  Renaudineau et al., Clinical Immunology (2022) - PMID: n.a.
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
  Sheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
  Dicks et al., BioRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (S-RBD), SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observation
  Arruda et al., Immunology (2022) - PMID: 35212005
  Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein)
• Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
  Abravanel et al., Vaccines (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipients
  Heinzel et al., MedRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Limited Recognition of Highly Conserved Regions of SARS-CoV-2
  Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796
  Products used: PepMix™ SARS-CoV-2 (Nsp12), SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)
• Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipients
  Zhang et al., Transplant Infectious Diseases (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patients
  Peter et al., Molecular Therapy (2022) 
  Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (AP3A), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / Omicron), HCMVA (pp65)
• Evaluation of IL-1β and IL-6 expression following EBNA-1 and BRLF-1 peptide treatment in Epstein Barr virus-positive multiple sclerosis patients
  Kianfar et al., Intervirology (2022)
• Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccination
  Tormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804
  Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variant
  Panikkar et al., Pathogens (2022) - PMID: 35157735
  Products used: PepMix™ SARS-CoV-2 (AP3A), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (Spike Glycoprotein)
• Polyfunctional pathogen-specific CD4+ T cells reside in the lungs and tumors of NSCLC patients
  Oja et al., BioRxiv (2022)
  Products used: PepMix™ HRSVB (Fusion Glycoprotein F0) & HRSVB (MSG)
• T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
  Vivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386
  Products used:  PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (AP3A), SARS-CoV-2 (Spike B.1.617.2 / Delta)
• Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys
  Amarendra Pegu et al., Cell Report (2022) - PMID: 34986348
  Products used: PepMix™ HIV-1 (ENV) Ultra
• Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct
  Shamin Li et al., OncoImmunology (2022) - PMID: n.a.
  Products used: PepMix™ HCMVA (pp65)
• Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people
  Joana Vitallé et al., medRxiv (2022) - PMID: n.a.
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients
  Eva Schrezenmeier et al., MedRxiv (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents
  Nina Koerber et al., Nature Communications (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination
  Nico Andreas et al., Vaccines (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
  Shinya Abe et al., Immunotherapy of Cancer (2022)
  Products used: PepMix™ HIV-1 (GAG) Ultra
• Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccination
  Laura Esparcia-Pinedo et al., MedRxiv (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1), SARS-CoV-2 (NCAP), SARS-CoV-2 (Nsp5)
• Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1
  Bo-Yi Sung et al., Journal of Clinical Investigation (2022) - PMID: 35040433
  Products used: PepMix™ HCMVA (pp65)
• Clinical and Immunological Characteristics for BK Polyomavirus- associated Nephropathy after Kidney Transplantation
  Tanaya Siripoon et al., Research Square (2022)
  Products used: PepMix™ BKV (capsid protein VP1), BKV (large T antigen)
• T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
  Lichen Jing et al., MedRxiv et al., (2022)
  Products used: PepMix™ HCoV-OC43 (Spike Glycoprotein)
• Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
  Bajwa et al., MedRxiv (2022)
• Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseases
  Dayam et al., MedRxiv (2022)
• Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
  Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481
  Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VME1)
• Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19
  Österdahl et al., MedRxiv (2022) 
• Differential localization and limited cytotoxic potential of duodenal CD8+ T cells
  Mvaya et al., JCI Insight (2022) - PMID: 35132966
  Products used: PepMix™ HIV-1 (POL), HIV-1 (GAG) & HIV-1 (NEF) 
• Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
  Lázaro-Frías et al., Vaccines (2022) 
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)
• mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
  Gagne et al., BioRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)
• A Co-stimulatory CAR Improves TCR-based Cancer Immunotherapy
  Omer et al., Cancer Immunology Research (2022) - PMID: 35176142
  Products used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2)
• Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
  Prodrazil et al., MedRxiv (2022)
  Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Archive

• Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted Patients
  Monica Miele et.al., American Journal of Transplantation (2021) - PMID: 34058052
• CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal Coronaviruses
  Katie E Lineburg et.al., Immunity (2021) - PMID: 33945786
• Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
  Pete Sieling et.al., medRxiv (2021) - PMID: n.a.
• Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors
  Stone et al., Human Gene Therapy (2021) - PMID: 32998579
  
• Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-B
  Jun Liu et.al., bioRxiv (2021) - PMID: n.a.
• A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2
  Martin P Steinbuck et.al., Sci Adv. (2021) - PMID: 33446655
• SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in Mice
  Jing-Hui Tian et.al., Nat Commun (2021) - PMID: 33446655
• Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 Study
  Jingxin Li et.al., Nat Med. (2021) - PMID: 33888900
• BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2
  Annette B Vogel et.al., Nature (2021) - PMID: 33524990
• Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63es
  Giulietta Saletti et.al., Sci Rep. (2021) - PMID: 33293664
• SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and Vaccinees
  Daryl Geers et.al., Sci Immunol. (2021) - PMID: 34035118
• COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral Responses
  Agnes Bonifacius et.al., Immunity (2021) - PMID: 33567252
• IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent Individuals
  Michal A Stanczak et.al., Nat Commun. (2021) - PMID: 33837219
• A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 Patients
  Henning Zelba et.al., J Immunol. (2021) - PMID: 33298615
• SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19
  Julian Braun et.al., Nature (2021) - PMID: 32726801
• Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic Coronaviruses
  Arbor G Dykema et.al., J Clin Invest. (2021) - PMID: 33830946
• Culture Media Optimization for Chinese Hamster Ovary Cell Growth and Expression of Recombinant Varicella-Zoster Virus Glycoprotein E
  Kwang Sung Kim et.al., Cytotechnology (2021) - PMID: 33897103
• SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody Responses
  Marco Mandolesi et.al., Cell Reports Medicine (2021) - PMID: 33842900
• SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 Variants
  Daniele Lilleri et.al., Research Square (2021) - PMID: n.a.
• Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of Concern
  Alexander C. Dowell et.al., medRxiv (2021) - PMID: n.a.
• Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
  Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211
• Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent Macaques
  Romain Marlin et.al., Nature Communications (2021) - PMID: n.a.
• Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009
  Samuel T. Pellom et.al., JCI Insight (2021) - PMID: 33651712
• Cytomegalovirus-Specific T-Cell Reconstitution Following Letermovir Prophylaxis after Hematopoietic Cell Transplantation
  Danniel Zamora et.al., In Press, Journal Pre-proof (2021) - PMID: 33657225
• Optimization of Zika DNA Vaccine by Delivery Systems
  Yun Ha Lee et.al., Virology (2021) - PMID: 33780719
• Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative Colitis
  Rachele Ciccocioppo et.al., Clinical and Experimental Medicine (2021) - PMID: 33772380
• Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection
  Chang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725
• Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
  Jianmin Zuo et.al., Nature (2021) - PMID: 33674800
• SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing Responses
  George W. Carnell et.al., bioRxiv (2021) - PMID: n.a.
• First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
  Fengcai Zhu et.al., Research Square (2021) - PMID: n.a.
• Validation of an IFN-Gamma ELISpot Assay to Measure Cellular Immune Responses Against Viral Antigens in Non-Human Primates
  Fan Yang et.al., Gene Ther. (2021) - PMID: 33432123
• Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept
  Nathalie Chavator et al., Transplantation, (2021)
• SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered Subjects
  Juan Zhao et al., Virus Res, (2021)
• Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
  Floriane Gallais et al., Emerg Infect Dis, (2021)
• SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After Infection
  Richardson, J.R. et al., ISAR Bioscience, (2021)
• COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
  Soo-Kyung Jeong et al., Vaccines, (2021)
• M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain
  Joseph Eiden et al., J Infect Dis, (2021)
• Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin Case
  Fabiana Gil-Melgaço et al., Viruses, (2021)
• Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies
  Florent Malard et al., Blood Cancer J, (2021)
• CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike
  Pavla Taborska et al., Front Immunol, (2021)
• T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19
  Mario Fernández-Ruiz et al., Am J Transplant, (2021)
• Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers
  Jackson, B.M. et al., BMC Infect Dis, (2021)
• Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant Recipients
  Tina Schmidt et al., Am J Translplant, (2021)
• The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the Neonate
  Sarah Gee et al., Nat Immunol, (2021)
• A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model
  Surapong Koonpaew et al., Vaccines, (2021)
• Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell Immunity
  Sabatino, J.J. et al., MedRxiv, (2021)
• Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
  Elizabeth Gabitzsch et al., BioRxiv, (2021)
• Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation
  Bejanyan, J. et al., Transplant Cell Ther, (2021)
• The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and Delta
  Reza Keikha et al., Sci Rep, (2021)
• Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
  King R.G. et al., Vaccines, (2021)
• T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory Study
  Rakesh Sindhi et al., MedRxiv, (2021)
• SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity
  Ji Yeun Kim et al., Am J Trop Med Hyg, (2021)
• Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 Infection
  Theodor Chitlaru et al., Pathogens, (2021)
• Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
  Punnee Pitisuttihum et al., MedRxiv, (2021)
• Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 Convalescence
  Tongcui Ma et al., BioRxiv, (2021)
• SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic Influence
  Olena Kalashnyk et al., Biochem Biophys Res Commun, (2021)
• CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected Patients
  Lucille Adam et al., JCI Insight, (2021)
• Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman Primates
  Joseph R. Francica et al., Sci Transl Med, (2021)
• Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFs
  Shira Weingarten-Gabbay et al., Cell, (2021)
• A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID
  Alberto Utrero-Rico et al., Biomedicines, (2021)
• COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 Challenge
  DiPiazza, A.T. et al., Immunity, (2021)
• Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA Vaccines
  Blakney, A.K. et al., J Control Release, (2021)
• An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent Immunity
  Anne-Catherine Fluckiger et al., Vaccine, (2021)
• Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in Mice
  Adrian Rice et al., Sci Rep, (2021)
• Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 Vaccination
  Daisy Massay et al., MedRxiv, (2021)
• Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 Vaccine
  Giménez, E. et al., J Infect (2021)
• Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
  Vidal, S-J. et al., J Virol, (2021)
• Application of Spectral Library Prediction for Parallel Reaction Monitoring of Viral Peptides
  Grossegesse, M. et al., Proteomics, (2021)
• Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination
  Simon Faissner et al., Res Square, (2021)
• Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 month
  Laurent Renia et al., Res Square, (2021)
• SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
  Joshua M. Carmen et al., Vaccines, (2021)
• mRNA Vaccine Protects against Zika Virus
  Lex G. Medina-Magües et al., Vaccines, (2021)
• A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
  M. Gordon Joyce et al., Science Translational Medicine
• SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19
  Mario Fernández-Ruiz et al., Transplantation, (2021)
• First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers
  Fenne L. Komdeur et al., Mol Ther, (2021)
• SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity
  Daniel Mrak et al., Ann Rheum Dis, (2021)
• Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2
  Krystle Kq Yu et al., JCI Insight, (2021)
• Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
  Chang Kyung Kang et al., J Infect Dis, (2021)
• Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity
  Alexander A. Lehmann et al., Front Immunology, (2021)
• Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 Patients
  Xiuyuan Lu et al., J Exp Med, (2021)
• Cytomegalovirus Specific Polyfunctional T-Cell Responses Expressing CD107a Predict control of CMV Infection After Liver Transplantation
  Ângela Carvalho-Gomes et al., Cellular Immunology, (2021)
• Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant Recipients
  Jeremy D. Rubinstein et al., Transplant Cell Ther, (2021)
• Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune Responses
  Ramachandran Thiruvengadam et al., Lancet Infect Dis, (2021)
• Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
  Samuel Bitoun et al., Arthritis & Rheumatology, (2021)
• Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
  Sarah P.H. van den Berg et al., Front Immunology, (2021)
• Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseases
  Samuel Bitoun et al., Arthritis & Rheumatology (2021) - PMID: 34962357
• Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus Infection
  Sara P H van den Berg et al., Front Immunology (2021) - PMID: 34025665

• CMV-Specific Immunity Recovers Slowly after Cord Blood Compared with Matched Sibling Donor Allogeneic Transplantation
  N.Bejanyan et.al., Transplantation and Cellular Therapy (2020) - PMID: n.a.
• Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients
  Shelley Waters et.al., Noncoding RNA. (2020) - PMID: 33353107
• Persistent Cellular Immunity to SARS-CoV-2 Infection
  Gaëlle Breton et.al., bioRxiv (2020) - PMID: 33330867
• Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
  Beatriz Olea et.al., medRxiv (2020) - PMID: n.a.
• 1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation Assays
  Begoña Pérez-Cabezas et.al., medRxiv (2020) - PMID: n.a.
• BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T Cells in Humans
  Ugur Sahin et.al., medRxiv (2020) - PMID: n.a.
• Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance- and Cognate Cross-Reactivity
  Alexander A. Lehmann et.al., bioRxiv (2020) - PMID: n.a.
• Guidelines For Analysis of Low-Frequency Antigen-Specific T Cell Results: Dye-Based Proliferation Assay vs 3H-Thymidine Incorporation
  Daniela Di Blasi et.al., Journal of Immunological Methods (2020) - PMID: 33152332
• Antigenic Competition in the Generation of Multi-Virus-Specific Cell Lines for Immunotherapy of Human Cytomegalovirus, Polyomavirus BK, Epstein-Barr Virus and Adenovirus Infection in Haematopoietic Stem Cell Transplant Recipients
  Kateřina Roubalová et.al., Immunol Lett. (2020) - PMID: 33031870
• Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease
  Thomas Hueso et.al., Blood (2020) - PMID: 32959052
• mRNA Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus Neutralizing Antibodies and Mediates Protection in Rodents
  Susanne Rauch et.al., bioRxiv (2020) - PMID: n.a.
• Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature Review
  Marta Lepore et.al., Transplant Infectious Disease (2020) - PMID: 33070461
• Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
  Anna E. Oja et.al., European Journal of Immunology (2020) - PMID: 33073359
• Characteristicsof Rapamycin-Treated T Cell Products for Advanced Adoptive T Cell Therapy and Evaluation of Clinical Feasibility
  Leila Amini et.al., Dissertation (2020) - PMID: n.a.
• Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
  Gallais F. et.al., Emerg Infect Dis (2020) - PMID: n.a.
• T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
  Candon S. et.al., Am J Transplant (2020) - PMID: n.a.
• Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
  Evan J. Anderson et.al., New England Journal of Medicine (2020) - PMID: 32991794
• Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
  Mercado et.al., Nature (2020) - PMID: 32731257
• Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman Primates
  Corbett et.al., N Engl J Med (2020) - PMID: 32722908
• Divergent SARS-CoV-2-Specific T and B Cell Responses in Severe but not Mild COVID-19
  Oja et.al., bioRxiv (2020) - PMID: n.a.
• Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
  McKay et.al., Nature (2020) - PMID: 32647131
• Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases
  Stamatakis et.al., bioRxiv (2020) - PMID: n.a.
• SARS-CoV-2-Specific T Cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
  Neidleman et.al., bioRxiv (2020) - PMID: 32577663
• A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
  Payen et.al., medRXiv (2020) - PMID: n.a.
• SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
  Corbett et.al., bioRxiv (2020) - PMID: 32577634
• Presence of SARS-CoV-2 Reactive T Cells in COVID-19 Patients and Healthy Donors
  Braun et.al., Nature (2020) - PMID: 32726801
• SARS‐CoV‐2‐Reactive Interferon‐γ‐Producing CD8+ T Cells in Patients Hospitalized with Coronavirus Disease 2019
  Estela Giménez et.al., Journal of Medical Virology (2020) - PMID: 32579268
• Evaluation of T-Activated Proteins as Recall Antigens to Monitor Epstein–Barr Virus and Human Cytomegalovirus-Specific T Cells in a Clinical Trial Setting
  Nina Körber et.al., Journal of Translational Medicine (2020) - PMID: 32552697
• Modified Alphavirus-Vesiculovirus Hybrid VaccineVectors for Homologous Prime-Boost Immunotherapyof Chronic Hepatitis B
  Carolina Chiale et.al., Vaccines (2020) - PMID: 32517032
• Duration of Cellular and Humoral Responses After Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adultswith or Without Prior Type 16 and/or 18 Exposure
  Lilin Lai et.al., Vaccines (2020) - PMID: n.a.
• A SARS-CoV-2 mRNA Vaccine — Preliminary Report
  Lisa A Jackson et.al., N Engl J Med (2020) - PMID: 32663912
• HBV‐Specific CD8 T Cells Present Higher TNFα Expression But Lower Cytotoxicity in Hepatocellular Carcinoma
  Ludong Zhao et.al., Clinical & Experimental Immunology (2020) - PMID: 32474905
• Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given Via Standard, Accelerated, or Shortened Schedules: a Single-Centre, Double-Blind, Sequential-Group, Randomised, Placebo-Controlled, Phase 1 Trial
  Kathryn E Stephenson et.al., The Lancet Infectious Diseases (2020) - PMID: n.a.
• Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional Assay
  Charlotte J. Houldcroft et.al., Cell-Mediated Immunity to HCMV (2020) - PMID: n.a.
• Evaluation of Glycoprotein E Subunit And Live Attenuatedvaricella‐Zoster Virus Vaccines Formulated With Asingle‐Strand RNA‐Based Adjuvant
  Su Jeen Lee et.al., Immunity, Inflammation and Disease (2020) - PMID: 32167678
• Women Who Received Varicella Vaccine Versus Natural Infection Have Different Long-Term T Cell Immunity but Similar Antibody Levels
  Ellen Tourtelot et.al., Vaccine (2020) - PMID: 31959424
• TGF‐β Promotes The Function Of HIV‐Specific CXCR5+CD8 T Cells
  Hong-Ge Yang et.al., Microbiology and Immunology (2020) - PMID: 32221997
• Persistent Expansion And Th1-Like Skewing of HIV-Specific Circulating T Follicular Helper Cells During Antiretroviral Therapy
  Julia Niessl Wu et.al., EBioMedicine (2020) - PMID: 32268275
• Preserved Specific Anti-Viral T-Cell Response But Associated With Decreased Lupus Activity In SLE Patients With Cytomegalovirus Infection
  Chien-Sheng Wu et.al., British Society for Rheumatology (2020) - PMID: 32306043
• A Chimeric Yellow Fever-Zika Virus Vaccinecandidate Fully Protects Against Yellow Fever Virusinfection in Mice
  Dieudonné Buh Kum et.al., Emerging Microbes & Infections (2020) - PMID: 32116148
• Efficacy, Immunogenicity, and Safety of an Oral Influenza Vaccine: a Placebo-Controlled And Active-Controlled Phase 2 Human Challenge Study
  David Liebowitz et.al., The Lancet Infectious Diseases (2020) - PMID: 31978354
• Immunogenicity of Novel mRNA COVID-19 Vaccine MRT5500 in Mice and 2 Non-Human Primates
  Kirill V. Kalnin et.al., Cancer Discovery (2019) - PMID: n.a.
• Tracking Dye‐Independent Approach to Identify and Isolate In Vitro Expanded T Cells
  George Elias et.al., Journal of Quantitative Cell Science (2019) - PMID: 31356002
• Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice
  Rafael A.Larocca et.al., Clinical and Translational Report (2019) - PMID: 31668877
• Tumor-Infiltrating B Cells Affect the Progression of Oropharyngeal Squamous Cell Carcinoma Via Cell-To-Cell Interactions With CD8+ T Cells
  Kamila Hladikova et.al., Journal for ImmunoTherapy of Cancer (2019) - PMID: 31623665
• PD-1 Blockade and TLR7 Activationlack Therapeutic Benefit in Chronic SIV-Infected Macaqueson Antiretroviral Therapy
  Elena Bekerman et.al., Antimicrob. Agents Chemother. (2019) - PMID: 31501143
• Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant Recipients
  Nandini Makwana et.al., Viral Immunology (2019) - PMID: 31536468
• Generation of HPV-Specific T-Cells
  Carlos A. Ramos et.al., United States Patent Application 20190224302 (2019) - PMID: n.a.
• A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig Model
  E.M.Kennedy et.al., Vaccine (2019) - PMID: 31331770
• A Novel Simplified Method of Generating Cytomegalovirus-Specific Cytokine-Induced Killer Cells of High Specificity and Superior Potency with GMP Compliance
  Yen Hoon Luah et.al., Clinical Immunology (2019) - PMID: 31229666
• Generation of Zika Virus–Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or “Off-the-Shelf” Immunotherapeutic
  Ryo Hanajiri et.al., Cytotherapy (2019) - PMID: n.a.
• HBeAg Seroconversion is Associated with a More Effective PD-L1 Blockade During Chronic Hepatitis B Infection
  Sara Ferrando-Martinez et.al., JHEP Reports (2019) - PMID: n.a.
• Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases
  Saritza Santos et.al., Journal of Immunology Research (2019) - PMID: n.a.
• Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or Prophylaxis
  Ajit P Limaye et.al. ,The Journal of Infectious Diseases (2019) - PMID: n.a.
• Phenotypic and Functional Differences Between HHV-6 and HCMV Specific T-Cells
  Solène Fastenackels et.al. , Journal of Virology (2019) - PMID: 30996090
• Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay
  Irene Cassaniti et.al. , PLoS Pathogens (2019) - PMID: n.a.
• T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy
  Allison S. Thomas et.al. , PLoS Pathogens (2019) - PMID: 28931091
• Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs
  Dae-Hee Sohn et.al. , PLoS ONE (2019) - PMID: 26023769
• Efficient Induction of Cell-Mediated Immunity to Varicella-Zoster Virus Glycoprotein E Co-Lyophilized with a Cationic Liposome-Based Adjuvant in Mice
  Seo Ri Wui et.al. , Vaccine (2019) - PMID: 30827737
• Penalized Supervised Star Plots: Example Application in Influenza-Specific CD4+ T Cells
  Tyson H. Holmes et.al. , Viral Immunology (2019) - PMID: 30698511
• Antigen-Specific TCR Signatures of Cytomegalovirus Infection
  Alina Huth et.al. , The Journal of Immunology (2018) - PMID: 30587531
• Developmental Induction of Human T-cell Responses Against Candida Albicans and Aspergillus Fumigatus
  Katrin Vogel et.al. , Scientific Reportsvolume (2018) - PMID: 30442915
• Activation of Resident Memory T Cells for Cancer Immunotherapy
  Masopust Jr et.al. , United States Patent Application 20180325952 (2018) - PMID: n.a.
• Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell Immunotherapy
  M Kalra et.al. , Cytotherapy (2018) - PMID: 30396848
• Generating HPV Antigen-specific Cells from a Native T Cell Population
  CM Bollard et.al. , US Patent App. 15/771,648, 2018 (2018) - PMID: n.a.
• Method For Preparing Genetically-Modified T Cells Which Express Chimeric Antigen Receptor
  Nishio et.al. , United States Patent Application 20180289742 (2018) - PMID: n.a.
• PI Highlight
  LL Kelley , PACT Newsletter (2018) - PMID: n.a.
• Replication Deficient Human Adenovirus Vector Serotype 19a/64: Immunogenicity in Mice and Female Cynomolgus Macaques
  Ragonnaud et al., Vaccine (2018) - PMID: 30190120
• Establishment and Operation of a Third Party Virus-Specific T-Cell Bank Within an Allogeneic Stem Cell Transplant Program
  Withers et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 30172015
• Humoral and Cellular Immunity to RSV in Infants, Children and Adults
  Green et al., Vaccine (2018) - PMID: 30177258
• Altered CD4+ T‐Cell Immunity in Nurses Occupationally Exposed to Viral Pathogens
  Elias et al., Clin Exp Immunol (2018) - PMID: 30076783
• Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant Recipients
  Arasaratnam et al., American Journal of Transplantation (2018) - PMID: 29900673
• Pepmixes To Generate Multiviral Ctls With Broad Specificity
  Leen et al., US Patent App. 15/905,176, (2018) - PMID: n.a.
• Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients
  Suárez-Lledó et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753162
• Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency
  Miller et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753156
• Employment of the Human Thymus as an Alternative Source of Regulatory T-Cells to Develop an Immunotherapy to Prevent Rejection in Transplanted Children
  Bernaldo de Quirós et al., Cytotherapy (2018) - PMID: n.a.
• Production of Quadrivalent Virus-Specific T Cells Utilizing Peptide Stimulation
  A. Damen et al., Cytotherapy (2018) - PMID: n.a.
• An Antigen-Free, Plasmacytoid Dendritic Cell–Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman Primates
  Masuta et al., J Immunol. (2018) - PMID: 29431693
• Multi-Antigenic Human Cytomegalovirus mRNA Vaccines that Elicit Potent Humoral and Cell-Mediated Immunity
  John et al., Sci Rep. (2018) - PMID: 29456015
• Cytomegalovirus-Specific T-Cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIV
  Ballegaard et al., Sci Rep. (2018) - PMID: 29491459
• Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood
  Corrales et al., Mol Ther Methods Clin Dev. (2017) - PMID: 28480300
• IL28B Genetic Variation and Cytomegalovirus-Specific T-cell Immunity in Allogeneic Stem Cell Transplant Recipients.
  Corrales et al., Journal of Medical Virology (2015) - PMID: 27591738
• Mycobacteria-Specific Cytokine Responses Detect TB Infection and Distinguish Latent from Active TB
  Tebruegge et al., Am J Respir Crit Care Med. (2015) - PMID: 26030187
• Method for Preparing Antigen-Specific Cytotoxic T-Cells by Using Activated B-Cells and use Thereof
  Kang et al., United States Patent Application 20180023054 (2018) - PMID: n.a.
• Production of Trivalent Antigen-Specific T Cells Utilizing Viral Peptide Stimulation
  Heyenbruch et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.
• Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection
  Kiniry et al., The Journal of Immunology (2018) - PMID: 29352005
• "Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients"
  Lee et al., Plos One (2017) - PMID: 29232714
• Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus (EEHV)
  Fuery et al., Journal of Virology (2017) - PMID: 29263271
• Follistatin-Like Protein-1 Upregulates Dendritic Cell-Based Immunity in Patients with Nasopharyngeal Carcinoma
  Wang Hong et al., Journal of Interferon & Cytokine Research (2017) - PMID: 29135371
• Methods of Cell Culture for Adoptive Cell Therapy
  Vera et al., US Patent 20,170,267,973, 2017 (2017) - PMID: n.a.
• The Effect of Genetic Variants Affecting NK Cell Function on Cardiovascular Health and the Burden on CMV
  Waters et al., Hum Immunol. (2017) - PMID: 28987961
• Protein Structure Shapes Immunodominance in the CD4 T cell Response to Yellow Fever Vaccination
  Koblischke et al., Sci Rep. (2017) - PMID: 28827760
• Immunologic Profiling of Human Metapneumovirus (hMPV) Towards the Development of a Targeted Immunotherapy
  Tzannou et al., The Journal of Infectious Diseases (2017) - PMID: n.a
• Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: an Open-label, Non-randomised, Prospective, First-in-human Phase 1 Clinical Trial
  Alberer et al., Lancet. (2017) - PMID: 28754494
• Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells
  Sung et al., EBioMedicine (2017) - PMID: 28803740
• CpG Oligonucleotides Increase HBV-Specific Cytokine Responses in Whole Blood and Enhance Cytokine Release Assay Sensitivity
  Dammermann et al., J Virol Methods (2017) - PMID: 28739303
• Elucidating CD8+ T-Cell Responses in the Rectal Mucosa During HIV Infection
  Kiniry et al., ProQuest (2017) - PMID: n.a.
• Vaccination with a Codon-Optimized A27L-Containing Plasmid Decreases Virus Replication and Dissemination After Vaccinia Virus Challenge
  Martínez et al., Vaccine (2017) - PMID: 28629922
• Pre-Transplant Immune Factors May be Associated with BK Polyomavirus Reactivation in Kidney Transplant Recipients
  DeWolfe et al., Plos one (2017) - PMID: 28562595
• Decitabine Treatment Sensitizes Tumor Cells to T-Cell-Mediated Cytotoxicity in Patients with Myelodysplastic Syndromes
  Zheng Zhang et al., Am J Transl Res (2017) - PMID: 28337274
• An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney Transplantation
  Dekeyser et al., Kidney International Reports (2017) - PMID: n.a.
• Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and Disease
  Khan et al., International Jounal of Cancer (2017) - PMID: 28263390
• Breadth of T Cell Responses after Immunization with Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus Antigens
  Ragonnaud et al., Scandinavian Journal of Immunology (2017) - PMID: 28109028
• Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs
  Schlott et al., Plos One (2017) - PMID: 28129395
• Perturbed CD8+ T Cell TIGIT/CD226/PVR Axis Despite Early Initiation of Antiretroviral Treatment in HIV Infected Individuals
  Tauriainen et al., Scientific Reports (2017) - PMID: 28084312
• Development of Novel Replication-defective Lymphocytic Choriomeningitis Virus Vectors Expressing SIV Antigens
  MacMaster et al., Vaccine (2016) - PMID: 27899229
• T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System
  Huang et al., Journal of Immunology (2016) - PMID: 28031333
• Polynucleotides For Treating Oncogenic Viral Polypeptide Positive Tumors
  Lee et al., US Patent 20,160,376,324 (2016) - PMID: n.a.
• Therapeutic Vaccine Targeting Epstein-Barr Virus Latent Protein, LMP1, Suppresses LMP1-Expressing Tumor Growth and Metastasis in Vivo
  Lin et al., BMC Cancer (2016) - PMID: 28056887
• Immune Monitoring to Predict and Prevent Infection
  Palmer et al., US Patent 20,160,377,602, 2016 (2016) - PMID: na.
• Predominance of Weakly Cytotoxic, T-betLowEomesNeg CD8+ T-Cells in Human Gastrointestinal Mucosa: Implications for HIV Infection.
  Kiniry et al., Mucosal Immunology (2016) - PMID: 27827375
• Expression of DAI by an Oncolytic Vaccinia Virus Boosts the Immunogenicity of the Virus and Enhances Antitumor Immunity
  Hirvinen et al., Molecular Therapy (2016) - PMID: 27626058
• αβ T Cell Receptor Germline CDR Regions Moderate Contact with MHC Ligands and Regulate Peptide Cross-Reactivity
  Attaf et al., Scientific Reports (2016) - PMID: 27775030
• Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoring
  von Hoegen et al., (2016) - PMID: n.a.
• The Challenge of Complexity: Peptide Tools for the Development of Immunotherapies
  Schnatbaum et al., (2016) - PMID: n.a.
• Circulating Functional T Cells Specific to HHV6 Antigens in Individuals With Chromosomally Integrated HHV-6 (ciHHV6)
  Barozzi et al., Clinical Microbiology and Infection (2016) - PMID: 27404369
• Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral Therapy
  Leng et al., HIV Medicine (2016) - PMID: 27649852
• Immune Responses Elicited by the GEN-003 Candidate HSV-2 Therapeutic Vaccine in a Randomized Controlled Dose-Ranging Phase 1/2a Trial
  Flechtner et al., Vaccine (2016) - PMID: 27642130
• Functional Diversity of CMV-Specific T-Cells is Maintained in Older People and Significantly Associated with Protein Specificity and Response Size
  Bajwa et al., The Journal of Infetious Diseases (2016) - PMID: 27521364
• Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge
  Magini et al., PloS one (2016) - PMID: 27525409
• Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation
  Schaenman et al., Transplantation (2016) - PMID: 27391197
• Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys
  Abbink et al., Science (2016) - PMID: 27492477
• Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host
  Schurich et al., Cell reports (2016) - PMID: 27452473
• Complementary Effects of IL-15 and IFN-α Induce Immunity in HBV Transgenic Mice
  Di Scala et al., Journal of virology (2016) - PMID: 27440883
• Composition and Dynamics of the Uterine NK Cell KIR Repertoire in Menstrual Blood
  Ivarsson et al., Mucosal Immunol. (2016) - PMID: 27271316
• Validation of an IFNγ/IL2 FluoroSpot Assay for Clinical Trial Monitoring
  Körber et al., J Transl Med. (2016) - PMID: 27297580
• A Single Exercise Bout Enhances the Manufacture of Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer Immunotherapy
  Spielmann et al., Sci Rep (2016) - PMID: 27181409
• Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly
  Theeten et al., Viral Immunology (2016) - PMID: 27002465
• Reconstitution of Cytomegalovirus-Specific T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients: the Contribution of Six Frequently Recognized, Virus-Encoded ORFs
  Nemeckova et al., Transpl Infect Dis. (2016) - PMID: 27061389
• The VZV/IE63-Specific T Cell Response Prevents Herpes Zoster in Fingolimod-Treated Patients
  Mathias et al., Neurology (2016) - PMID: n.a.
• Cytotoxic Polyfunctionality Maturation of Cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell Responses in Older Adults Positively Correlates with Response Size
  Chiu et al., Sci Rep. (2016) - PMID: 26778409
• Restoring Tissue-Like Functionality in Circulating CD8 T-Cells: Mechanistic Studies and Application in Immunomonitoring of Cancer Patients
  Wegner et al., Thesis for a doctoral degree at the Graduate School of Life Sciences, University Würzburg, Germany (2016) - PMID: n.a.
• In Vitro Studies of the Impact of Maribavir on CMV-Specific Cellular Immune Responses
  Stachel et al., J Clin Virol. (2015) - PMID: 26780109
• Generation of Broadly-Specific, Virus-Immune Cells Targeting Multiple HIV Antigens For Prenventive and Therapeutic Use
  Bollard et al., US Patent 20,150,359,876 (2015) - PMID: n.a.
• Recombinant Particle Based Vaccines Against Human Cytomegalovirus Infection
  Wellnitz et al., US Patent 20,150,359,879 (2015) - PMID: n.a.
• Induction Of Broad-Based Immunity and Protective Efficacy by Self-Amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin
  Brazzoli et al., Journal of Virology (2015) - PMID: 26468547
• Functionally Active HIV-Specific T Cells that Target gag and nef Can Be Expanded from Virus-Naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT
  Patel et al., Biology of Blood and Marrow Transplantation (2015) - PMID: n.a.
• Characteristics of Immune Memory 10–15 years After Primary Hepatitis B Vaccination
  Hummel et al., Vaccine (2015) - PMID: n.a.
• IL-12–Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control
  Popescu et al., J Immunol. (2015) - PMID: 26663780
• Safety of Human Immunisation With a Live-attenuated Mycobacterium Tuberculosis Vaccine: a Randomised, Double-blind, Controlled Phase I Trial
  Spertini et al., The Lancet Respiratory Medicine (2015) - PMID: n.a
• Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Non-radioactive Measurement of Cellular and Humoral Cytotoxicity
  Omokoko et al., Journal of Immunology Research (2015) - PMID: n.a.
• A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-unit Vaccine Antigens
  Swaminathan et al., Vaccine (2015) - PMID: 26555351
• Peptide Libraries for the Comprehensive Coverage of the Tumor Mutanome for Immune Monitoring and Immuno Therapy
  von Hoegen et al., Journal for ImmunoTherapy of Cancer (2015)- PMID: n.a.
• Prognostic Impact of Circulating Her-2-reactive T-cells Producing Pro- and/or anti-inflammatory Cytokines in Elderly Breast Cancer Patients
  Bailur et al., J Immunother Cancer. (2015) - PMID: 26500775
• Targeting of Nucleoprotein to Chemokine Receptors by DNA Vaccination Results in Increased CD8+-mediated Cross Protection Against Influenza
  Baranowska et al., Vaccine (2015) - PMID: 26387432
• An Immunoinformatic Approach for Identification of Trypanosoma cruzi HLA-A2-Restricted CD8+ T cell Epitopes
  Eickhoff et al., Hum Vaccin Immunother. (2015) - PMID: 26107442
• Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with Panobinostat
  Olesen et al., Journal of Virology (2015) - PMID: 26223643
• Chimpanzee Adenovirus– and MVA-Vectored Respiratory Syncytial Virus Vaccine is Safe and Immunogenic in Adults
  Green et al., Science Translational Medicine. (2015) - PMID: n.a
• Efficacy of a Virus-Vectored Vaccine Against Human and Bovine Respiratory Syncytial Virus Infections
  Taylor et al., Science Translational Medicine. (2015) - PMID: n.a
• Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis
  Stuehler et al., The Journal of Infectious Disease. (2015) - PMID: 25748323
• CD4+CD28null T Lymphocytes Resemble CD8+CD28null T Lymphocytes in Their Responses to IL-15 and IL-21 in HIV-infected Patients
  Echeverría et al., J. Leukoc. Biol. (2015) - PMID: 26034206
• Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell Transplantation
  Pietersma et al., J Clin Cell Immunol (2015) - PMID: n.a
• T Cells Specific for Different Latent and Lytic Viral Proteins Efficiently Control Epstein-Barr Virus–Transformed B Cells
  Nowakowska et al., Cytotherapy (2015) - PMID: 26276009
• Methods of Cell Culture for Adoptive Cell Therapy
  Vera et al., US Patent 20,150,175,966, 2015 - PMID: n.a
• High-Density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived Antigens
  Wegner et al., Blood (2015) - PMID: 26024876
• Metabolic Regulation of Hepatitis B Immunopathology by Myeloid-derived Suppressor Cells
  Pallett et al., Nature Medicine (2015) - PMID: 25962123
• ABO‐Desensitization Affects Cellular Immunity and Infection Control after Renal Transplantation
  Schachtner et al., Transplant International (2015) - PMID: 26033637
• The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled Trial
  Geldenhuys et al., Vaccine (2015) - PMID: 26048780
• Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase Iia Randomized Clinical Trial
  Munseri et al., PloSOne (2015) - PMID: 25875843
• Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients
  Friedrich et al., Am J Transplant. (2015) - PMID: 26137874
• Guidelines For the Automated Evaluation of Elispot Assays
  Janetzki et al., Nature Protocols (2015) - PMID: 26110715
• Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency
  Schmueck-Henneresse, The Journal of Immunology (2015) - PMID: 25917088
• A Comparative Phase 1 Clinical Trial to Identify Anti-infective Mechanisms of Vitamin D in People With HIV Infection
  Lachmann et al., AIDS (2015) - PMID: 25870995
• HCV-Specific Lymphocyte Responses in Individuals with Positive Anti-HCV but Negative HCV-RNA
  Sili et al., Journal of Clinical Virology (2015) - PMID: n.a.
• Safety and Immunogenicity of a Modified Vaccinia Ankara-based HIV-1 Vaccine (MVA-B) in HIV-1-Infected Patients Alone or in Combination with a Drug to Reactivate latent HIV-1
  Mothe et al., J Antimicrob Chemother. (2015) - PMID: 25724985
• A Single Bout of Dynamic Exercise by Healthy Adults Enhances the Generation of Monocyte-Derived-Dendritic Cells
  LaVoy et al., Cellular Immunology (2015) - PMID: n.a.
• Discordant Humoral and Cellular Immune Responses to Cytomegalovirus (CMV) in Glioblastoma Patients Whose Tumors are Positive for CMV
  Rahbar et al., OncoImmunology (2015) - PMID: n.a.
• Early Transduction Produces Highly Functional Chimeric Antigen Receptor-modified Virus-specific T-cells with Central Memory Markers: a Production Assistant for Cell Therapy (PACT) Translational Application
  Sun et al., J Immunother Cancer. (2015) - PMID: 25734008
• Role of Naïve-Derived T Memory Stem Cells in T Cell Reconstitution Following Allogeneic Transplantation
  Roberto et al., Blood. (2015) - PMID: 25742699
• Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold Infections
  Stuehler et al., The Journal of Infectious Disease (2015) - PMID: 25367298
• Mycobacterium Tuberculosis-Specific and MHC Class I-Restricted CD8+ T-Cells Exhibit a Stem Cell Precursor-Like Phenotype in Patients with Active Pulmonary Tuberculosis
  Axelsson-Robertson et al., Int J Infect Dis. (2015) - PMID: 25809750
• The Loss of BKV-Specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication
  Schachtner et al., Am J Transplant. (2015) - PMID: 25808077
• Diagnostics Reagents
  Jones et al., US Patent 20,150,093,766 (2015) - PMID: n.a.
• CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells
  Wang et al., Clin Cancer Res. (2015) - PMID: 25838392
• Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant Conditions
  Freimüller et al., Cytotherapy (2015) - PMID: 25866178
• Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells
  Marquardt et al., J Immunol. (2015) - PMID: 25672754
• Potential role of CC Chemokine Receptor 6 (CCR6) in Prediction of Late‐onset CMV Infection Following Solid Organ Transplant
  Camargo et al., Clin Transplant. (2015) - PMID: 25690781
• Polynucleotides for Treating Oncogenic Viral polypeptide Positive Tumors
  Lee et al., US Patent 20,150,023,996, (2015) - PMID: n.a.
• Functional Exhaustion limits CD4+ and CD8+ T Cell Responses to Congenital Cytomegalovirus Infection
  Huygens et al., J Infect Dis. (2015) - PMID: 25657256
• Early Exposure to Interleukin-21 Limits Rapidly Generated Anti–Epstein-Barr Virus T-cell Line Differentiation
  Orio et al., Cytotherapy. (2015) - PMID: 25661862
• STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
  Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338
• Human Papillomavirus 16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
  Tong et al., J Infect Dis. (2015) - PMID: 25139018
• Intracellular Cytokine Staining on PBMCs Using CyTOFTM Mass Cytometry
  Lin et al., bio-protocol.org - PMID: n.a.
• The External Quality Assurance Oversight Laboratory (EQAPOL) Proficiency Program for IFN-gamma Enzyme-Linked ImmunoSpot (IFN-γ ELISpot) Assay
  Sanchez et al., J Immunol Methods. (2014) - PMID: n.a.
• Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine Trials
  Sambor et al., J Immunol Methods. (2014) - PMID: 24787274
• CMV Specific Cytokine Release Assay in Whole Blood is Optimized by Combining Synthetic CMV Peptides and Toll Like Receptor Agonists
  Dammermann et al., Journal of Immunological Methods (2014) - PMID: n.a.
• Naïve and Memory CD8 T Cell Pool Homeostasis in Advanced Aging: Impact of Age and of Antigen-specificRresponses to Cytomegalovirus
  Vescovini et al., Age (Dordr). (2014) - PMID: 24318918
• Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients
  Lúcia et al., Clinical Infectious Diseases (2014) - PMID: 25048845
• A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
  Taylor et al., Clin. Cancer Res. (2014) - PMID: 25124688
• Human B Cells Produce Chemokine CXCL10 in the Presence of Mycobacterium Tuberculosis Specific T Cells
  Hoff et al., Tuberculosis (2014) - PMID: n.a.
• Expression of the Human Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T Cells
  Gabaev et al., Journal of Virology (2014) - PMID: 25275132
• HPV16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions
  Tong et al., J Infect Dis. (2014) - PMID: 25139018
• Immune Responses Againgst Mycobacterium Tuberculosis Targets Associated to Latent and Active Tuberculosis Infection
  Montserrat Alvarez-Corrales, Published by Karolinska Institutet (2014) - PMID: n.a.
• Preferential Infection of Human Ad5-Specific CD4 T Cells by HIV in Ad5 Naturally Exposed and Recombinant Ad5-HIV Vaccinated Individuals
  Hu et al., PNAS (2014) - PMID: 25197078
• Diminished Humoral Responses Against and Reduced Gene Expression Levels of Human Endogenous Retrovirus-K (HERV-K) in Psoriasis
  Gupta et al., Journal of Translational Medicine (2014) - PMID: 25224121
• Gene Therapy for Rhesus Monkeys Heterozygous for LDL Receptor Deficiency by Balloon Catheter Hepatic Delivery of Helper-Dependent Adenoviral Vector
  Oka et al., Gene Therapy (2014) - PMID: 25231173
• Superior In Vitro Stimulation of Human CD8+ T-Cells by Whole Virus versus Split Virus Influenza Vaccines
  Halbroth et al., PLoS One (2014) - PMID: PLoS One (2014)
• Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT
  Papadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991
• Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
  Fourati et al., JoVE (2014) - PMID: 25046399
• The Role of CD4+ T Cells in BKV-Specific T Cell Immunity
  Weist et al., Med Microbiol Immunol. (2014) - PMID: 25052009
• NetFCM: A Semi-Automated Web-Based Method for Flow Cytometry Data Analysis
  Frederiksen et al., Cytometry A. (2014) - PMID: 25044796
• T-Bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection
  Buggert et al., PLoS Pathog. (2014) - PMID: 25032686
• Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope Prediction
  Schwaiger et al., J Virol. (2014) - PMID: 24789782
• Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunological Responses
  Weide et al., American Association for Cancer Research (2014) - PMID: n.a
• BK Polyomavirus‐Specific Cellular Immune Responses Are Age‐Dependent and Strongly Correlate With Phases of Virus Replication
  Schmidt et al., American Journal of Transplantation (2014) - PMID: 24726000
• MART-1 Peptide Vaccination Plus IMP321 (LAG-3Ig fusion protein) in Patients Receiving Autologous PBMCs After Lymphodepletion: Results of a Phase I Trial
  Romano et al., Journal of Translational Medicine (2014) - PMID: 24726012
• TLR2-Dependent Protection Against Pneumococcal Carriage by Immunization with Lipidated Pneumococcal Proteins
  Moffitt et al., Infection and Immunol. (2014) - PMID: 24614661
• An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory Syncytial Virus F-Specific IFNγ-producing T Cells
  Patton et al., Clin Vaccine Immunol. (2014) - PMID: 24574540
• Influence of Frequent Infectious Exposures on General and Varicella-zoster Virus Specific Immune Responses in Pediatricians
  Ogunjimi et al., Clin Vaccine Immunol. (2014) - PMID: 24429070
• Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome
  Loebl et al., PLOS ONE (2014) - PMID: 24454857
• HIV Infection in Uncircumcised Men Is Associated With Altered CD8 T-cell Function But Normal CD4 T-cell Numbers in the Foreskin
  Prodger et al., The Journal of Infectious Diseases (2014) - PMID: 24277744
• Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
  Bollard et al., J Clin Oncol. (2013) - PMID: 24344220
• Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies that Prevent Infection of Fibroblasts and Epithelial Cells
  Cayatte et al., J. of Virology (2013) - PMID: 23926341
• Mechanistic Insights Into the Impairment of Memory B Cells and Antibody Production in the Elderly
  Aberle et al., AGE (2013) - PMID: 22282053
• Detection of Epstein-Barr Virus-Specific Memory CD4+ T Cells Using a Peptide-Based Cultured Enzyme-Linked Immunospot Assay
  Calarota et al., Immunology (2013) - PMID: 23560877
• Nonreplicating Vaccines Can Protect African Green Monkeys from the Memphis 37 Strain of Respiratory Syncytial Virus
  Eyles et al., Journal of Infectious Diseases (2013) - PMID: 23596321
• Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical Trials
  Kutscher et al., PLoS One (2013) - PMID: 24146841
• Inflammatory Activation and Recovering BKV-specific Immunity Correlate with Self-Limited BKV Replication after Renal Transplantation
  Schachtner et al., Transplant International (2013) - PMID: 24279642
• Adoptive Immunotherapy with Antigen-Specific T Cells During Extracorporeal Membrane Oxygenation (ECMO) for Adenovirus-Related Respiratory Failure in a Child Given Haploidentical Stem Cell Transplantatio
  Di Nardo et al., Pediatric Blood & Cancer (2013) - PMID: 24039155
• Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive Immunotherapy
  Ricciardelli et al., American Journal of Transplantation (2013) - PMID: 24266973
• The Immunogenicity of Virus-Derived 2A Sequences in Immunocompetent Individuals
  Arber et al., Gene Therapy (2013) - PMID: 23698740
• Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
  Chia et al., Molecular Therapy (2013) - PMID: 24297049
• Combination of Epstein-Barr Virus Nuclear Antigen 1, 3 and Lytic Antigen BZLF1 Peptide Pools Allows Fast and Efficient Stimulation of Epstein-Barr Virus-Specific T Cells for Adoptive Immunotherapy
  Wang et al., Cytotherapy (2013) - PMID: 24094498
• A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular Pathology
  Terrazzini et al., The Journal of Infectious Disease (2013) - PMID: 24203779
• Putting Polyphosphates to the Test: Evidence Against Platelet-Induced Activation of Factor XII
  Faxälv et al., Blood (2013) - PMID: 23896408
• Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application
  Geyeregger et al., PLOS ONE (2013) - PMID: 23630567
• Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
  Icheva et al., JCO (2013) - PMID: 23169501
• Human Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated Malignancies
  Ramos et al., Journal of Immunotherapy (2013) - PMID: 23211628
• Cytomegalovirus-Specific CD4 and CD8 T Cell Responses in Infants and Children
  Lidehäll et al., Scandinavian Journal of Immunology (2013) - PMID: 23216075
• The Effects of Age and Latent Cytomegalovirus Infection on the Redeployment of CD8+ T Cell Subsets in Response to Acute Exercise in Humans
  Spielmann et al., Brain, Behavior, and Immunity (2013) - PMID: 23684819
• The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells
  Schurich et al., PLOS Pathogens (2013) - PMID: 23516358
• Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
  Blaney et al., PLOS Pathogens (2013) - PMID: 23737747
• Donor-Derived CMV-Specific T Cells Reduce The Requirement For CMV-Directed Pharmacotherapy After Allogeneic Stem Cell Transplantation
  Blyth et al., Blood. (2013) - PMID: 23435462
• Antigen-Reactive T Cell Enrichment for Direct, High-Resolution Analysis of the Human Naive and Memory Th Cell Repertoire
  Bacher et al., J. Immunol. (2013) - PMID: 23479226
• An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs
  Skoberne et al., J. Virol. (2013) - PMID: 23365421
• Distinct Gene-Expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 Infection
  Hu et al., Blood. (2013) - PMID: 23258923
• IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-Antigens
  Deshpande et al., J. Immunol. (2013) - PMID: 23325887
• Up-Regulation of a Death Receptor Renders Antiviral T Cells Susceptible to NK Cell–Mediated Deletion
  Peppa et al., J. Exp. Med. (2012) - PMID: 23254287
• Reconstitution of Protective Immune Responses against Cytomegalovirus and Varicella Zoster Virus Does Not Require Disease Development in Pediatric Recipients of Umbilical Cord Blood Transplantation
  Merindol et al., J. Immunol. (2012) - PMID: 23034171
• Antiviral T Cell Response Triggers Cytomegalovirus Hepatitis in Mice
  Livingston-Rosanoff et al., J. Virol. (2012) - PMID: 22993151
• Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys
  Stephenson et al., J. Virol. (2012) - PMID: 22896617
• Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial Infection
  Chua et al., Infect. Immun. (2012) - PMID: 22778103
• Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic Hyperplasia
  Sais et al., J. Virol. (2012) - PMID: 22647697
• Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A Infection
  Eller et al., J Acquir Immune Defic Syndr (2012) - PMID: 22580564
• A Novel Th Cell Epitope of Candida albicans Mediates Protection from Fungal Infection
  Bär et al., J. Immunol. (2012) - PMID: 22529294
• Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T Cells in the Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodies
  de Jongste et al., Neuro Oncology. (2012) - PMID: 22591661
• Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant Recipients
  Clari et al., Clin Vaccine Immunol May (2012) - PMID: 22379065
• The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope
  de Souza et al., J. Immunol. (2012) - PMID: 22529301
• Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells
  Schmueck et al., J. Immunol. (2012) - PMID: 22516956
• T-Cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical Results
  Secondino et al., Ann. Onc. (2012) - PMID: 21586688
• A Whole Blood Monokine-Based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell Response
  Chakera et al., Journal of Translational Medicine (2011) - PMID: 21871084
• Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children
  Hoft et al., The Journal of Infectious Disease (2011) - PMID: 21846636
• Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV
  Mellberg et al., AIDS Research and Therapy (2011) - PMID: 21708049
• A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-LMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal Carcinoma
  Chia et al., Ann. Onc. (2011) - PMID: 21821548
• Polyomavirus BK Large T-Antigen Derived Peptide Elicits a HLA-DR Promiscuous and Polyfunctional CD4+ T-cell Response
  Ramaswami et al., Clin. Vaccine Immunol (2011) - PMID: 21367979
• Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein – Barr Virus and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell Transplantation
  Hanley et al., Cytotherapy (2011) - PMID: 21539497
• Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
  Louis et al., J Immunother (2010) - PMID: 20948438
• Effective and Long-Term Control of EBV PTLD After Transfer of Peptide-Selected T Cells
  Moosmann et al., Blood (2010) - PMID: 20103780
• Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)
  Vera et al., J Immunother. (2010) - PMID: 20445351
• Derivation of Human T Lymphocytes From Cord Blood and Peripheral Blood with Antiviral and Antileukemic Specificity from a Single Culture as Protection Against Infection and Relapse after Stem Cell Transplantation
  Micklethwaite et al., Blood (2010) - PMID: 20110422
• Absence of Systemic Immune Response to Adenovectors After Intraocular Administration to Children With Retinoblastoma
  Ildefonso et al., Molecular Therapy (2010) - PMID: 20606647
• Nucleofection of DCs to Generate Multivirusspecific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised Host
  Gerdemann et al., Molecular Therapy (2009) - PMID: 19584818
• Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell Transplantation
  Leen et al., Blood (2009) - PMID: 19700662
• Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells
  Lindenstrom et al., J. Immunol (2009) - PMID: 19494330
• Enhancing the In Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients
  Louis et al., Blood (2009) - PMID: 18971421
• Mesenchymal Stem Cells Exert Differential Effects on Alloantigen and Virus-Specific T-cell Responses
  Karlsson et al., Blood (2008) - PMID: 18445691
• Prospective Monitoring of Polyomavirus BK Replication and Impact of Pre-Emptive Intervention in Pediatric Kidney Recipients
  Ginevri et al., American Journal of Transplantation (2007) - PMID: 17908275
• Contact-Activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells
  Leen et al., J Immunother (2007) - PMID: 17198088